Re: Effects of rosiglitazone on hormonal profile and ovulatory function in Chinese women with polycystic ovary syndrome [1]

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 46, Issue 2, 2006, Pages 170-171

  Chan, Louis Y ^a   Lau, Tze K ^a   Fung, Tze M ^b   Chow, Kam M ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b PRINCESS MARGARET HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; FOLLITROPIN; INSULIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROGESTERONE; ROSIGLITAZONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ANOVULATION; BODY MASS; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPERANDROGENISM; LETTER; LUTEAL PHASE; MENSTRUAL CYCLE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; CHINA; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLICLE STIMULATING HORMONE; FOLLOW-UP STUDIES; HUMANS; LUTEINIZING HORMONE; MENSTRUAL CYCLE; OVULATION; POLYCYSTIC OVARY SYNDROME; PROGESTERONE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 33645345439     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2006.00550.x     Document Type: Letter

References (9)

1. Azziz R, Ehrmann D, Legro RS et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86: 1626-1632.
2. Mitwally MFM, Duscu NK, Yalcinkaya TM. High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum Reprod 1999; 14: 2700-2703.
3. Tarkun I, Cetinarslan B, Turemen E, Sahin T, Canturk Z, Komsuoglu B. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol 2005; 153: 115-121.
4. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 562-566.
5. Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 2005; 90: 60-65.
6. Dereli D, Dereli T, Bayraktar F, Ozgen AG, Yilmaz C. Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J 2005; 52: 299-308.
7. Williamson K, Gunn AJ, Johnson N, Milsom SR. The impact of ethnicity on the presentation of polycystic ovarian syndrome. Aust N Z J Obstet Gynaecol. 2001; 41: 202-206.
8. Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 1992; 167: 1807-1812.
9. Lam PM, Ma RC, Cheung LP, Chow CC, Chan JC, Haines CJ. Polycystic ovarian syndrome in Hong Kong Chinese women: Patient characteristics and diagnostic criteria. Hong Kong Med J 2005; 11: 336-341.